dr. scagliotti on treating egfr-mutated tumors with afatinib
Published 10 years ago • 228 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:25
dr. giorgio scagliotti discusses afatinib in patients with egfr mutation
-
1:37
dr. scagliotti discusses egfr mutations in nsclc
-
0:54
dr. scagliotti on egfr targeted therapy survival benefits
-
1:47
dr. scagliotti on mechanisms of resistance to egfr tkis
-
3:47
afatinib therapy for uncommon egfr alterations in nsclc
-
1:47
dr. west on fda approval of afatinib in nsclc with rare egfr mutations
-
4:09
frontline afatinib in egfr-mutant nsclc
-
1:00
dr. scagliotti discusses the future of lung cancer therapy
-
1:32
dr. scagliotti discusses elderly lung cancer therapy
-
1:35
dr. janjigian discusses afatinib and cetuximab for patients with egfr-mutant lung cancer
-
8:38
afatinib plus cetuximab in resistant non-small cell lung cancer
-
1:17
dr. scagliotti gives 3 important lung cancer takeaway points
-
1:59
dr. scagliotti on lung cancer treatment-related toxicities
-
1:30
dr. langer on afatinib for advanced non-small cell lung cancer
-
3:30
osimertinib for uncommon egfr mutations in nsclc
-
0:45
dr. corey langer discusses afatinib in egfr-positive nsclc
-
1:49
dr. scagliotti on toxicities related to surgery and chemotherapy in patients with lung cancer
-
1:22
dr. scagliotti discusses the future of multiple gene profiles
-
1:25
dr. bunn discusses afatinib in lung cancer